Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma

Oncology Reports

Volumn 25, Issue 2, 2011, Pages 399-407

  De La Cruz Hernández, Erick ^a   Perez Plasencia, Carlos ^a   Pérez Cardenas, Enrique ^a   Gonzalez Fierro, Aurora ^a   Trejo Becerril, Catalina ^a   Chávez Blanco, Alma ^a   Taja Chayeb, Lucia ^a   Vidal, Silvia ^a   Gutiérrez, Olga ^a   Dominguez, Guadalupe I ^a   Trujillo, Jaenai E ^a   Duenas González, Alfonso ^b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Cervical cancer; Epigenetic therapy; Hydralazine; Microarray; Valproate

Indexed keywords

CISPLATIN; HYDRALAZINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEASOME; RIBOSOME PROTEIN; VALPROATE MAGNESIUM; WNT PROTEIN;

ACTIN FILAMENT; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CELL ADHESION; CELL CYCLE; CYTOSKELETON; DOWN REGULATION; EPIGENETICS; FEMALE; FOCAL ADHESION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TIGHT JUNCTION; UPREGULATION; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDRALAZINE; MICROARRAY ANALYSIS; TRANSCRIPTION, GENETIC; UP-REGULATION; UTERINE CERVICAL NEOPLASMS; VALPROIC ACID;

EID: 78651363567     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1086     Document Type: Article

References (35)

1. Hellebrekers DM, Griffioen AW and van Engeland M: Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta 1775: 76-91, 2007. (Pubitemid 44895568)
2. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, Aragno M and Boccuzzi G: Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191: 465-472, 2006. (Pubitemid 44830622)
3. Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S and Grant S: The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64: 2590-2600, 2004. (Pubitemid 38523917)
4. Yeow WS, Ziauddin MF, Maxhimer JB, Shamimi-Noori S, Baras A, Chua A, Schrump DS and Nguyen DM: Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. Br J Cancer 94: 1436-1445, 2006. (Pubitemid 43772278)
5. Chávez-Blanco A, Pérez-Plasencia C, Pérez- Cárdenas E, Carrasco-Legleu C, Rangel-Lopez E, Segura-Pacheco B, Taja- Chayeb L, Trejo-Becerril C, Gonzalez-Fierro A, Candelaria M, Cabrera G and Duenas-Gonzalez A: Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 6: 2, 2006.
6. Forrer C, Hofstetter B and Pruschy M: Treatment with demethylating agent 5-Aza-2'-Deoxy-Cytidine (DAC) leads to enhanced sensitivity to ionizing radiation (IR) in colorectal carcinoma. Radiat Oncol 73: S1-S497, 2004.
7. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K and Tofilon PJ: Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 11: 4571-4579, 2005. (Pubitemid 40825648)
8. Camphausen K, Cerna D, Scott T, Sproull M, Burgan WE, Cerra MA, Fine H and Tofilon PJ: Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114: 380-386, 2005. (Pubitemid 40279957)
9. Karpf AR: Epigenomic reactivation screening to identify genes silenced by DNA hypermethylation in human cancer. Curr Opin Mol Ther 9: 231-241, 2007.
10. Shi H, Wei SH, Leu YW, Rahmatpanah F, Liu JC, Yan PS, Nephew KP and Huang TH: Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res 63: 2164-2171, 2003.
11. Li L, Shi H, Yiannoutsos C, Huang TH and Nephew KP: Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system. J Comput Biol 12: 370-390, 2005. (Pubitemid 40586439)
12. Arce C, Pérez-Plasencia C, González-Fierro A, de la Cruz- Hernandez E, Revilla-Vazquez A, Chavez-Blanco A, Trejo- Becerril C, Perez-Cardenas E, Taja-Chayeb L, Bargallo E, Villarreal P, Ramirez T, Vela T, Candelaria M, Camargo MF, Robles E and Duenas-Gonzalez A: A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 1: e98, 2006.
13. Candelaria M, Cetina L, Coronel J, Cantu D, Rivera L, Perez- Cardenas E, de la Cruz-Hernández E, Gonzalez-Fierro A, Chavez-Blanco A, Trejo-Becerril C, Taja-Chayeb L, Chanona J and Duenas-Gonzalez A: Epigenetic therapy added to cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynecol Oncol 31: 386-391, 2010.
14. Zhang B, Kirov S and Snoddy J: WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 33: W741-W748, 2005. (Pubitemid 44530021)
15. Perez-Plasencia C, Vazquez-Ortiz G, Lopez-Romero R, Pina- Sanchez P, Moreno J and Salcedo M: Genome wide expression analysis in HPV16 cervical cancer: identification of altered metabolic pathways. Infect Agent Cancer 2: 16, 2007.
16. Al-Shahrour F, Minguez P, Vaquerizas JM, Conde L and Dopazo J: Babelomics: a suite of web-tools for functional annotation and analysis of group of genes in high-throughput experiments. Nucleic Acids Res 33: W460-W464, 2005. (Pubitemid 44529962)
17. Gardiner-Garden M and Frommer M: CpG islands in vertebrate genomes. J Mol Biol 196: 261-282, 1987.
18. Rosenwald IB: The role of translation in neoplastic transformation from a pathologist's point of view. Oncogene 23: 3230-3247, 2004.
19. Ruggero D and Pandolfi PP: Does the ribosome translate cancer? Nat Rev Cancer 3: 179-192, 2003.
20. Amsterdam A, Sadler KC, Lai K, Farrington S, Bronson RT, Lees JA and Hopkins N: Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol 2: E139, 2004. (Pubitemid 39234481)
21. Draptchinskaia N, Gustavsson P, Andersson B, Pettersson M, Willig TN, Dianzani I, Ball S, Tchernia G, Klar J, Matsson H, Tentler D, Mohandas N, Carlsson B and Dahl N: The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anemia. Nat Genet 21: 169-175, 1999. (Pubitemid 29070361)
22. Wasser JS, Yolken R, Miller DR and Diamond L: Congenital hypoplastic anemia (Diamond-Blackfan syndrome) terminating in acute myelogenous leukemia. Blood 51: 991-995, 1978. (Pubitemid 8342566)
23. Lipton JM, Federman N, Khabbaze Y, Schwartz CL, Hilliard LM, Clark JI, Vlachos A; Diamond-Black Anemia Registry: Diamond-Black Anemia Registry: Osteogenic sarcoma associated with Diamond-Blackfan anemia: a report from the Diamond-Blackfan Anemia Registry. J Pediatr Hematol Oncol 23: 39-44, 2001. (Pubitemid 32140371)
24. Gazda HT, Kho AT, Sanoudou D, Zaucha JM, Kohane IS, Sieff CA and Beggs AH: Defective ribosomal protein gene expression alters transcription, translation, apoptosis, and oncogenic pathways in Diamond-Blackfan anemia. Stem Cells 24: 2034-2044, 2006. (Pubitemid 44477128)
25. Smeitink J, van den Heuvel L and DiMauro S: The genetics and pathology of oxidative phosphorylation. Nat Rev Genet 5: 342-352, 2001.
26. Mamelak AJ, Kowalski J, Murphy K, Yadava N, Zahurak M, Kouba DJ, Howell BG, Tzu J, Cummins DL, Liegeois NJ, Berg K and Sauder DN: Downregulation of NDUFA1 and other oxidative phosphorylation-related genes is a consistent feature of basal cell carcinoma. Exp Dermatol 14: 336-348, 2005. (Pubitemid 40691655)
27. Huang G, Lu H, Hao A, Ng DC, Ponniah S, Guo K, Lufei C, Zeng Q and Cao X: GRIM-19, a cell death regulatory protein, is essential for assembly and function of mitochondrial complex I. Mol Cell Biol 24: 8447-8456, 2004. (Pubitemid 39245067)
28. Wong TW, Yu HY, Kong SK, Fung KP and Kwok TT: The decrease of mitochondrial NADH dehydrogenase and drug induced apoptosis in doxorubicin resistant A431 cells. Life Sci 67: 1111-1118, 2000.
29. Rodríguez-Enriquez S, Vital-González PA, Flores-Rodríguez FL, Marin-Hernandez A, Ruiz-Azuara L and Moreno-Sanchez R: Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells. Toxicol Appl Pharmacol 215: 208-217, 2006. (Pubitemid 44190002)
30. Harper ME, Antoniou A, Villalobos-Menuey E, Russo A, Trauger R, Vendemelio M, George A, Bartholomew R, Carlo D, Shaikh A, Kupperman J, Newell EW, Bespalov IA, Wallace SS, Liu Y, Rogers JR, Gibbs GL, Leahy JL, Camley RE, Melamede R and Newell MK: Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J 16: 1550-1557, 2002.
31. Tomiyama A, Serizawa S, Tachibana K, Sakurada K, Samejima H, Kuchino Y and Kitanaka C: Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J Natl Cancer Inst 98: 1462-1473, 2006. (Pubitemid 44605591)
32. Perez-Plasencia C and Duenas-Gonzalez A: Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer 5: 27, 2006.
33. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006. (Pubitemid 44348499)
34. de la Cruz-Hernandez E, Perez-Cardenas E, Contreras-Paredes A, Cantu D, Mohar A, Lizano M and Duenas-Gonzalez A: The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. Virol J 4: 18, 2007. (Pubitemid 46391967)
35. Terui T, Murakami K, Takimoto R, Takahashi M, Takada K, Murakami T, Minami S, Matsunaga T, Takayama T, Kato J and Niitsu Y: Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors. Cancer Res 63: 8948-8954, 2003. (Pubitemid 38064075)